OSE Immunotherapeutics SA (LON: 0RAD)
London flag London · Delayed Price · Currency is GBP · Price in EUR
6.56
+0.09 (1.39%)
At close: Jan 22, 2025

OSE Immunotherapeutics Statistics

Total Valuation

OSE Immunotherapeutics has a market cap or net worth of GBP 118.76 million. The enterprise value is 91.81 million.

Market Cap 118.76M
Enterprise Value 91.81M

Important Dates

The last earnings date was Wednesday, January 1, 2025.

Earnings Date Jan 1, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class n/a
Shares Outstanding n/a
Shares Change (YoY) +22.97%
Shares Change (QoQ) +22.87%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 16.45M

Valuation Ratios

The trailing PE ratio is 3.04.

PE Ratio 3.04
Forward PE n/a
PS Ratio n/a
PB Ratio n/a
P/TBV Ratio 1.72
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.02, with an EV/FCF ratio of 1.86.

EV / Earnings 2.35
EV / Sales 1.30
EV / EBITDA 2.02
EV / EBIT 2.02
EV / FCF 1.86

Financial Position

The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.54.

Current Ratio 4.93
Quick Ratio 4.70
Debt / Equity 0.54
Debt / EBITDA 0.82
Debt / FCF 0.75
Interest Coverage 18.48

Financial Efficiency

Return on equity (ROE) is 88.54% and return on invested capital (ROIC) is 35.12%.

Return on Equity (ROE) 88.54%
Return on Assets (ROA) 30.41%
Return on Capital (ROIC) 35.12%
Revenue Per Employee 1.36M
Profits Per Employee 750,516
Employee Count 55
Asset Turnover 0.75
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +73.69% in the last 52 weeks. The beta is 0.96, so OSE Immunotherapeutics's price volatility has been similar to the market average.

Beta (5Y) 0.96
52-Week Price Change +73.69%
50-Day Moving Average 8.24
200-Day Moving Average 6.90
Relative Strength Index (RSI) 34.33
Average Volume (20 Days) 104

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, OSE Immunotherapeutics had revenue of GBP 70.74 million and earned 39.03 million in profits. Earnings per share was 1.71.

Revenue 70.74M
Gross Profit 70.74M
Operating Income 45.65M
Pretax Income 41.91M
Net Income 39.03M
EBITDA 44.90M
EBIT 45.65M
Earnings Per Share (EPS) 1.71
Full Income Statement

Balance Sheet

The company has 64.22 million in cash and 37.21 million in debt, giving a net cash position of 27.01 million.

Cash & Cash Equivalents 64.22M
Total Debt 37.21M
Net Cash 27.01M
Net Cash Per Share n/a
Equity (Book Value) 69.05M
Book Value Per Share 3.17
Working Capital 57.99M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 49.48 million and capital expenditures -28,826, giving a free cash flow of 49.45 million.

Operating Cash Flow 49.48M
Capital Expenditures -28,826
Free Cash Flow 49.45M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of 64.52% and 55.17%.

Gross Margin 100.00%
Operating Margin 64.52%
Pretax Margin 59.25%
Profit Margin 55.17%
EBITDA Margin 63.46%
EBIT Margin 64.52%
FCF Margin 69.90%

Dividends & Yields

OSE Immunotherapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -22.97%
Shareholder Yield -22.97%
Earnings Yield 32.86%
FCF Yield 41.64%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

OSE Immunotherapeutics has an Altman Z-Score of 3.94.

Altman Z-Score 3.94
Piotroski F-Score n/a